Celularity Inc. Announces CEO Change and Board Appointments
Ticker: CELUW · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1752828
Sentiment: neutral
Topics: management-change, board-appointments
Related Tickers: CELU
TL;DR
Celularity CEO out, new CEO in, two new board members appointed.
AI Summary
Celularity Inc. announced on August 27, 2024, several key executive and board changes. Dr. Robert J. Hariri has stepped down as Chief Executive Officer and will be succeeded by Dr. Steven J. Deitcher. Additionally, the company appointed two new directors, Ms. Pamela Maragliano-Muniz and Mr. David M. S. Johnson, to its Board of Directors.
Why It Matters
This filing indicates significant leadership transitions at Celularity Inc., which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty and affect strategic execution, warranting a medium risk assessment.
Key Players & Entities
- Celularity Inc. (company) — Registrant
- Dr. Robert J. Hariri (person) — Outgoing CEO
- Dr. Steven J. Deitcher (person) — Incoming CEO
- Ms. Pamela Maragliano-Muniz (person) — Appointed Director
- Mr. David M. S. Johnson (person) — Appointed Director
- GX Acquisition Corp. (company) — Former Company Name
FAQ
Who has been appointed as the new CEO of Celularity Inc.?
Dr. Steven J. Deitcher has been appointed as the new CEO of Celularity Inc.
Who is stepping down as CEO of Celularity Inc.?
Dr. Robert J. Hariri is stepping down as CEO of Celularity Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 27, 2024.
How many new directors were appointed to Celularity Inc.'s Board of Directors?
Two new directors, Ms. Pamela Maragliano-Muniz and Mr. David M. S. Johnson, were appointed.
What was Celularity Inc.'s former company name?
Celularity Inc.'s former company name was GX Acquisition Corp.
Filing Stats: 965 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2024-08-28 17:23:22
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share CELU The Nasdaq
- $11.50 — A Common Stock at an exercise price of $11.50 per share CELUW The Nasdaq Stock Ma
- $300,000 — Class A common stock having a value of $300,000 on the grant date, or 118,111 shares, u
- $3.01 — es. The option has an exercise price of $3.01 per share (the closing sales price of C
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 8KB
- 0001493152-24-034216.txt ( ) — 277KB
- celu-20240827.xsd (EX-101.SCH) — 4KB
- celu-20240827_def.xml (EX-101.DEF) — 29KB
- celu-20240827_lab.xml (EX-101.LAB) — 36KB
- celu-20240827_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: 99.1 Press Release dated August 28, 2024 104 Cover Page Interactive Data File (Embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC. Date: August 28, 2024 By: /s/ Robert J. Hariri Robert J. Hariri, M.D., Ph.D. Chairman and CEO